Breathe analysis
Our team investigates the use of SIFT-MS as a diagnostic tool for infectious disease (tuberculosis, influenza), cancer (lung, gastric, breast, colon, liver), drug abuse (ketamine), respiratory disease (asthma, chronic obstructive pulmonary disease), and cardiovascular disease (myocardial infarction).
Related Publications:
- “Estimation of clinical parameters of chronic kidney disease (CKD) by exhaled breath full-scan mass spectrometry data and Iterative PCA with Intensity Screening (IPS) algorithm”. J Breath Res. Volume 11, Issue 3, 21 August 2017, Article number 036007
- “Use of a least absolute shrinkage and selection operator (LASSO) model to selected ion flow tube mass spectrometry (SIFT-MS) analysis of exhaled breath to predict the efficacy of dialysis: a pilot study”, J Breath Res. 2016 Sep 28;10(4):046004.
Patent filed:
- PCT Patent filed: “Systems and methods using exhaled breath for medical diagnostics and treatment”, filed on 30 January 2014, PCT/CN2014/071853
- Provision Patent No. 61/793,532 “Systems and methods using exhaled breath for medical diagnostics and treatment”, filed on 15 March 2013
- Provisional Patent No. 61/759,808 “A System and Method using Exhaled Breath Through Mass Spectrometry for Diagnosis and Prognosis of Various Medical Conditions and Diseases”, filed on 1 Feb 2013
Grants:
- “A fast and non-invasive testing method for renal function and diabetes through selected ion flow tube mass spectrometry (SIFT-MS)”, General Research Fund of RGC, 2014-01-01 to 2015-12-31, $779,000.
